Compare Carvana Co (CVNA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs BIO-TECHNE Corp — how do they compare? Carvana Co trades at $71.88 (market cap $81.54B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Carvana Co is far larger — about 7.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Carvana Co pays none. Which is the better fit depends on your goals.
| CVNA | TECH | |
|---|---|---|
Market Cap | $81.54B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $72.29 |
52-Week Low | $56.27 | $43.31 |
Enterprise Value | $84.03B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $70.85, up 3.73% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, driven by record retail unit growth, though profit margins face pressure. The stock is near its consensus price target of $87.18, with analyst sentiment split between Buy and Hold ratings.
Outlook remains positive due to aggressive scaling and AI-driven cost efficiencies, but risks include high debt levels and competitive threats. Investors should weigh robust growth against valuation concerns, with the current P/E of 37.5 reflecting high expectations. Near-term performance hinges on execution of margin improvement goals.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
